M K PROTEINS

Date: 13.11.2026

To
The Manager
Listing Compliance
Bombay Stock Exchange Limited
P.J Towers, Dalal Street,
Mumbai-400 001
Maharashtra, India
SCRIP CODE: 543919

To
The Manager
Listing Compliance
National Stock Exchange of India Limited (NSE)
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai – 400051
NSE SYMBOL: MKPL

Subject: Outcome of the Board Meeting held today i.e. on 13th November 2026

Dear Sir/Madam,

Pursuant to the Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today i.e. on Friday, November 13th, 2026, *inter alia,* considered and approved the following matters:

1. Un-Audited Standalone Financial Results of the Company for the Quarter and half year ended September 30, 2026, together with a Statement of Cash Flow, Statement of Assets and Liabilities for the same period;
2. Limited Review Report on the aforesaid Financial Results of the Company for the Quarter and Half Year ended September 30, 2026, issued by the Statutory Auditors of the Company;
3. Related Party Transactions for the Half Year ended 30.09.2026;
4. Other Business(es);

The meeting of the Board of Directors commenced at 03:30 P.M. and concluded at 04:00 P.M.

You are requested to take the same on your record.

Thanking you,

Yours Faithfully,
FOR M K PROTEINS LIMITED

NEHA AGGARWAL
Digitally signed by NEHA AGGARWAL
Date: 2026.11.13 16:19:42 +05'30'

Neha Aggarwal
Company Secretary cum Compliance Officer

SUBHASH SAJAL & ASSOCIATES

Chartered Accountants
A Peer Reviewed Firm

1766, New Christian Colony,
Near Civil Hospital,
Jagadhri – 135003
M: 94166-84636, 98962-57600
Email: smittalca504@gmail.com
smittalca@rediffmail.com

Independent Auditor's Limited Review Report on the Unaudited Standalone Financial Results of M. K. Proteins Limited for the Quarter and Half Year ended 30th September 2026 pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
M. K. Proteins Limited
Naraingarh Road, Village Garnala,
Ambala City (Haryana), India - 134003

Ref : Limited Review Report of Unaudited Standalone Financial Results for the quarter ended 30th September, 2025 and year to date from 1st April, 2026 to 30th September, 2026

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **M. K. Proteins Limited** ("the Company") for the quarter ended September 30, 2026 and year to date from 1st April, 2026 to 30th September, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 (hereafter referred to as "the Regulations"), to the Stock Exchange.

2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. This statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on theses Financial Statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is of interim financial information consists of making inquiries, primarily of Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Financial Results, prepared in accordance with applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ambala

Date: 13th November 2026

For Subhash Sajal and Associates
Chartered Accountants
Firm Registration No. 018178N

(Sajal Mittal)
M. No. 576124
(Partner)
UDIN: 26576124QKFUTM6742

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003
T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN: L15500HR2012PLC046239 | ISIN: INE964W01021

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2026

(Rs. In Lacs)

		QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	
		30-09-2026 (UNAUDITED)	30-06-2026 (UNAUDITED)	30-09-2025 (UNAUDITED)	30-09-2026 (UNAUDITED)	30-09-2025 (UNAUDITED)	31-03-2026 (AUDITED)	31-03-2025 (AUDITED)
1.	**Revenue**							
a)	Revenue from Operation (Net)	4446.28	11516.12	3243.03	15962.40	14737.63	38287.52	26770.60
b)	Other Income	5.94	0.00	12.43	5.94	12.43	25.94	47.66
	Sub-Total "1"	4452.22	11516.12	3255.46	15968.34	14750.06	38313.46	26818.26
2.	**Expenditure**							
a)	Cost of Material Consumed	1991.74	9087.62	1657.04	11079.36	10427.78	28648.84	16674.36
b)	Purchase of Stock-in-Trade	822.09	1234.55	1118.65	2056.64	2807.41	7369.24	5149.41
c)	Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	1191.96	346.27	195.78	1538.23	342.09	(717.06)	2146.27
d)	Employees Benefits Expenses	77.48	78.44	53.58	155.92	107.28	302.77	274.52
e)	Manufacturing, Operating and Other Expenses	215.87	517.78	113.48	733.65	397.55	1541.98	1282.93
f)	Finance Costs	21.19	51.94	6.45	73.13	76.61	185.20	110.50
g)	Depreciation and Amortization Expenses	15.35	14.78	10.50	30.13	20.85	43.63	35.17
	Sub-Total "2"	4335.68	11331.38	3155.48	15667.06	14179.57	37374.60	25673.16
3	Profit/(Loss) before Exceptional, Extraordinary items and Tax [1 – 2]	116.54	184.74	99.98	301.28	570.49	938.86	1145.10
4	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit/(Loss) before Extraordinary items and Tax [3 – 4]	116.54	184.74	99.98	301.28	570.49	938.86	1145.10
6	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before Tax [5 – 6]	116.54	184.74	99.98	301.28	570.49	938.86	1145.10
8	**Tax Expenses**							
a)	Provision for Current Tax	33.30	45.93	22.90	79.23	141.05	246.79	301.86
b)	Provision for Deferred Tax Liability/(Adjustment)	(3.72)	0.57	2.41	(3.15)	3.45	5.21	3.50
c)	Prior Year Taxes	0.00	0.00	0.00	0.00	0.00	3.96	0.00
	Sub-Total "8"	29.58	46.50	25.31	76.08	144.50	255.96	305.36
9	Profit/(Loss) for the Period from continuing operations [7 - 8]	86.96	138.24	74.67	225.20	425.99	682.90	839.74
10	Profit/(Loss) for the period from Discontinuing operations before tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expenses of Discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(Loss) from Discontinuing operations (After Tax) [10 – 11]	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(Loss) for the period [9 + 12]	86.96	138.24	74.67	225.20	425.99	682.90	839.74
14	**Other Comprehensive Income net of taxes**							
a)	(i) Amount of items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.72	(1.51)
	(ii) Income Tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.18	(0.38)
b)	(i) Amount of items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Sub- Total "14"	0.00	0.00	0.00	0.00	0.00	0.54	(1.13)
15	Total comprehensive Income for the Period [13 + 14]	86.96	138.24	74.67	225.20	425.99	683.44	838.61

16	**Earnings per share**							
a)	Earnings per Equity Share for continuing operations							
	Basic earnings/(Loss) per share from continuing operations	0.02	0.04	0.02	0.06	0.11	0.18	0.22
	Diluted earning/(Loss) per share from continuing operations	0.02	0.04	0.02	0.06	0.11	0.18	0.22
b)	Earnings per Equity Share for discontinuing operations							
	Basic earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Diluted earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
c)	Earnings per Equity Share							
	Basic earning/(Loss) per share from continuing and discontinuing operations	0.02	0.04	0.02	0.06	0.11	0.18	0.22
	Diluted earning/(Loss) per share from continuing and discontinuing operations	0.02	0.04	0.02	0.06	0.11	0.18	0.22
17	**Details of Equity Share Capital**							
	Paid-up Equity Share Capital	3753.72	3753.72	3753.72	3753.72	3753.72	3753.72	3753.72
	Face value of Equity Share Capital	1	1	1	1	1	1	1
18	Other Equity [Reserves]	-	-	-	4101.50	3618.84	3876.30	3192.86

Note:

1. The above mentioned un-audited results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 13th November, 2026.
2. Previous year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
3. The above results have been reviewed by the Statutory Auditor as required under regulation 33 of SEBI (Listing Obligations and disclosures Requirements) Regulations, 2015.
4. The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate reportable segment.
5. Disclosure of assets and liabilities as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September, 2026 is given as per Annexure "I" attached

Place: Ambala

Dated: 13-11-2026

For and on behalf of the board

M. K. PROTEINS LTD. AMBALA (HARYANA)

(Parmod Kumar)
Managing Director
DIN: 00126965

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003
T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN: L15500HR2012PLC046239 | ISIN: INE964W01021

ANNEXURE "I"

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMEBR 2026 IS GIVEN BELOW: -

(in Rs. Lakhs)

	PARTICULARS	AS AT 30-09-2026 (UNAUDITED)	AS AT 30-09-2025 (UNAUDITED)	AS AT 31-03-2026 (AUDITED)
A	**ASSETS**			
1	**Non-Current Assets**			
	-Property, Plant and Equipment	377.67	269.94	397.25
	-Capital Work-in-Progress	709.77	669.66	709.77
	-Right of Use of Assets	72.73	79.05	75.90
	-Intangible assets	0.00	0.00	0.00
	Financial Assets			
	-Investments	0.00	0.00	0.00
	-Other financial assets	34.26	34.26	34.26
	Deferred Tax Assets (net)	32.10	30.90	28.95
	Other non-current assets	25.92	205.17	50.68
	Sub-Total "1" Non-Current Assets	1252.45	1288.98	1296.81
2	**Current Assets**			
	-Inventories	6098.77	5515.77	10978.20
	Financial Assets			
	-Investments	0.00	415.47	0.00
	-Trade Receivables	161.35	540.43	211.00
	-Cash and Cash Equivalents	198.76	20.46	43.82
	-Other Financial assets	0.00	0.00	0.00
	Other Current Assets	634.45	220.79	589.87
	Sub-Total "2" Current Assets	7093.33	6712.92	11822.89
	TOTAL ASSETS	**8345.78**	**8001.90**	**13119.70**
B	**EQUITY AND LIABILITIES**			
1	**Equity**			
	-Equity Share Capital	3753.72	3753.72	3753.72
	-Other Equity	4101.50	3618.84	3876.30
	Sub-Total "1" Total of Equity	7855.22	7372.56	7630.02
2	**Liabilities**			
	Non-Current Liabilities			
	Financial Liabilities			
	-Borrowings	69.68	62.72	104.51
	-Lease Liabilities	90.91	93.55	92.40
	-Other financial liabilities	0.00	0.00	0.00
	Provisions	38.90	32.55	38.33
	Other non-current liabilities	0.00	0.00	0.00
	Sub-Total Non-Current Liabilities	199.49	188.82	235.24
	Current Liabilities			
	Financial Liabilities			
	-Borrowings	68.17	39.86	3514.35
	-Lease Liabilities	2.76	2.51	2.51
	-Trade Payables			
	Total outstanding dues of micro enterprises and small enterprises	0.00	0.00	203.00
	Total outstanding dues of micro enterprises and small enterprises	29.41	69.00	300.60
	-Other Financial Liabilities	12.97	1.57	53.84
	Other Current Liabilities	129.40	126.55	1078.63

	Provisions	2.34	1.69	2.34
	Current Tax Liabilities (Net)	46.02	199.34	99.17
	Sub-Total Current Liabilities	291.07	440.52	5254.44
	TOTAL EQUITY AND LIABILITIES	**8345.78**	**8001.90**	**13119.70**

Place: Ambala
Dated: 13-11-2026

For and on behalf of the board

M. K. PROTEINS LTD. AMBALA (HARYANA)

(Parmod Kumar)
Managing Director
DIN: 00126965

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003
T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN: L15500HR2012PLC046239 | ISIN: INE964W01021

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2026

In Rs. Lakhs

	PARTICULARS	FOR THE HALF YEAR ENDED 30/09/2026 UNAUDITED	FOR THE HALF YEAR ENDED 30/09/2025 UNAUDITED	FOR THE YEAR ENDED 31/03/2026 AUDITED
A.	CASH FLOW FROM OPERATING ACTIVITIES			
	-Net Profit/(Loss) before tax	301.28	570.49	938.86
	-Adjustment for:-			
	Depreciation and amortisation expenses	30.13	20.85	43.63
	Interest Expenses	73.13	76.61	185.20
	Provision for Excepted credit loss allowance created/(written back)	0.00	0.00	3.31
	Provision for Retirement Gratuity Benefit to Employees	0.00	0.00	6.64
	Net Gain on Sale/Fair Valuation of Investment on FVTPL	0.00	(6.53)	(8.24)
	Interest Income	(5.94)	0.00	(11.80)
	(Profit)/ Loss on sale of fixed Assets (Vehicle)	0.00	(5.90)	(5.90)
	Operating profit before working capital changes	**398.60**	**655.52**	**1151.70**
	Adjustment for (Increase)/Decrease in operating assets:			
	-Trade Receivables	49.65	(400.11)	(73.98)
	-Inventories	4879.44	5616.71	154.28
	-Other Non-Current Assets	24.76	(101.87)	45.50
	-Other Current Assets	(44.58)	354.58	(14.50)
	Adjustment for Increase/(Decrease) in operating Liabilities:			
	-Trade Payables	(474.19)	(1862.45)	(1427.85)
	-Other Financial Current liabilities	(41.12)	(36.05)	16.36
	-Other Current Liabilities	(949.23)	(4.52)	947.55
	-Provisions	0.00	0.00	0.00
	Cash use in / generated from operation	3843.33	4221.81	799.06
	-Direct taxes paid	(132.38)	(45.82)	(255.69)
	NET CASH FROM OPERATING ACTIVITIES	**3710.95**	**4175.99**	**543.37**
B.	CASH FLOW FROM INVESTING ACTIVITIES			
	-Sale Proceed of fixed assets	0.00	9.50	9.50
	-Sale Proceeds for Investment in Mutual Funds	0.00	550 06	967.24
	-(Increase)/Decrease in Bank Balances not considered as Cash and Cash Equivalent	0.00	0.00	0.00
	-Purchase of Investment	0.00	(959.00)	(959.00)
	-Fixed Assets /Capital Work-in-progress Purchases	(7.38)	(9.60)	(189.52)
	-Other Non-Current Financial Assets (Securities)	0.00	0.00	0.00
	-Interest Income	5.94	0.00	11.80
	NET CASH FROM INVESTING ACTIVITIES	**(1.44)**	**(409.04)**	**(159.98)**

C.	CASH FLOW FROM FINANCING ACTIVITIES				
	-Increase/(Decrease) in Short term Bank Borrowings		(3450.87)	(3653.84)	(202.97)
	-Increase in Long Term Borrowings		0.00	0.00	84.92
	-Payment of Lease Liabilities		(6.00)	(6.00)	(12.00)
	-Repayment of long term borrowings		(30.15)	(18.74)	(38.24)
	-Finance cost		(67.55)	(71.29)	(174.66)
	NET CASH FROM FINANCING ACTIVITIES		(3554.57)	(3749.87)	(342.95)
	NET CASH FLOW DURING THE YEAR (A+B+C)		154.94	17.08	40.44
	Cash and Cash Equivalent at beginning of the period		43.82	3.38	3.38
	Cash and Cash Equivalent at end of the period		198.76	20.46	43.82

Place: Ambala

Dated: 13-11-2026

For and on behalf of the board

M. K. PROTEINS LTD. AMBALA (HARYANA)

(Parmod Kumar)
Managing Director
DIN: 00126965